Back From the Dead: What Dog Cloning Means for Our Human Future
By Osagie K. Obasogie,
Alternet
| 06. 16. 2008
Good Morning America recently televised a world exclusive that caught many pet owners' attention: Dog cloning is now commercially available for people who want to bring their dead and dying companions back to life. Brought to you by BioArts International, a Northern California biotech startup, man and his dead best friend can now be, as the company's marketing slogan states, "Best Friends Again." And again. And again.
But it'll cost you. Rather than taking orders, BioArts will auction off five dog cloning slots in mid-June. Bids start at $100,000.
Despite Good Morning America's numerous awards for excellence in televised journalism, its coverage of this story was not its finest moment. A number of omissions and oversights led the segment to present dog cloning as a largely unproblematic way to deal with the grief of our pets' inevitable deaths. But several untold stories behind this story need to be put front and center.
The ABC morning show presented BioArts' CEO Lou Hawthorne as the next in a long line of pioneering Californian bio executives. But rather than being a new venture...
Related Articles
By Alondra Nelson, Science | 01.15.2026
One of the most interventionist approaches to technology governance in the United States in a generation has cloaked itself in the language of deregulation. In early December 2025, President Donald Trump took to Truth Social to announce a forthcoming “One...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...